Effectiveness and Safety of Shengmai San for Viral Myocarditis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Cardiovascular Therapeutics · 2024-01 · 2024 (1)
DOI: 10.1155/2024/2127018 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Therapeutics, online erschienen am 20.06.2024. Verfasst von Bing-Rui Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Evidence-Based Chinese Medicine Beijing University of Chinese Medicine, Beijing 100029, China. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Drugs, Chinese Herbal, Myocarditis, Drug Combinations. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Shengmai San (SMS) is a traditional Chinese medicine formula used for supplementing Qi and Yin and can mitigate symptoms related to malignant arrhythmia and heart failure. This systematic review aimed at exploring the effectiveness and safety of SMS for viral myocarditis (VMC).
Methods
Eight databases from their inception to June 2023 were searched to identified randomized controlled trials (RCTs) focusing on SMS for VMC. The Cochrane Risk of Bias Tool was used to assess methodological quality. Mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) with 95% confidence interval (CI) were calculated and input into the meta‐analysis using RevMan 5.4.
Results
Forty‐four RCTs were included involving 4298 participants. The interventions included 29 types of modified SMS decoctions and 15 patent medicines. Overall study quality was low. Compared with western medicine (WM), SMS was associated with higher recovery rate from palpitations (RR 2.3, 95% CI 1.59, 3.33, 2 RCTs, n = 89), chest pain (RR 1.57, 95% CI [1.17, 2.09], 2 RCTs, n = 89), and lower cTnI (MD −0.82 ng/ml, 95% CI −0.98, −0.66, 1 RCT, n = 60). SMS plus WM was more effective than WM in palpitation recovery rate (RR 1.52, 95% CI 1.21, 1.92, 3 RCTs, n = 136), dyspnea recovery rate (RR 1.47, 95% CI 1.12, 1.94, 3 RCT, n = 267), ECG (RR 1.43, 95% CI 1.32, 1.55, 20 RCT, n = 2035), CK‐MB (MD −6.36, 95% CI −8.43, −4.28, 8 RCT, n = 946), and cTnI (MD −0.06, 95% CI −0.06, −0.05, 3 RCT, n = 307). No serious adverse events were reported using SMS alone or in combination with WM.
Conclusion
SMS used alone or combined with WM may have potential effectiveness on symptom alleviation, ECG recovery rate, myocardial injury markers, and cardiac function, but the effectiveness is uncertain due to the low quality and absence of placebo‐controlled trials. The exact efficacy of SMS for VMC needs to be confirmed by high‐quality double‐blind RCTs in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Evidence-Based Chinese Medicine Beijing University of Chinese Medicine, Beijing 100029, China.
- Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing 100700, China.
- Dongfang Hospital Beijing University of Chinese Medicine, Beijing 100078, China.
- Guangdong Provincial Research Center of Integration of Traditional Chinese Medicine and Western Medicine in Metabolic Diseases (Institute of Chinese Medicine) Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Intensive Care Unit Beijing Hospital of Traditional Chinese Medicine, Beijing 100010, China.
- Institute of Health and Social Care London South Bank University, London, UK.
ORCID-Profile: Jian-Ping Liu
Zitieren
APA
Zhang, B. R., Liu, X. H., Ling, Y. T., Lu, C. L., Jin, X. Y., Wei, Y. M., Cai, Y. Q., Robinson, N., & Liu, J. P. (2024). Effectiveness and Safety of Shengmai San for Viral Myocarditis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Cardiovascular Therapeutics, 2024(1). https://doi.org/10.1155/2024/2127018
Vancouver
Zhang BR, Liu XH, Ling YT, Lu CL, Jin XY, Wei YM, et al. Effectiveness and Safety of Shengmai San for Viral Myocarditis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Cardiovascular Therapeutics. 2024;2024(1). doi:10.1155/2024/2127018
BibTeX
@article{Zhang2024,
author = {Zhang, Bing-Rui and Liu, Xue-Han and Ling, Yu-Tong and Lu, Chun-Li and Jin, Xin-Yan and Wei, Yi-Ming and Cai, Yi-Qing and Robinson, Nicola and Liu, Jian-Ping},
title = {Effectiveness and Safety of Shengmai San for Viral Myocarditis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Cardiovascular Therapeutics},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/2127018}
}
EUVIMED